164 related articles for article (PubMed ID: 38393465)
1. The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast.
Pandithar S; Galke D; Akume A; Belyakov A; Lomonaco D; Guerra AA; Park J; Reff O; Jin K
Mol Biol Rep; 2024 Feb; 51(1):331. PubMed ID: 38393465
[TBL] [Abstract][Full Text] [Related]
2. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.
Zou A; Lambert D; Yeh H; Yasukawa K; Behbod F; Fan F; Cheng N
BMC Cancer; 2014 Oct; 14():781. PubMed ID: 25344051
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
4. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
[TBL] [Abstract][Full Text] [Related]
5. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
6. CXCL1 stimulates migration and invasion in ER‑negative breast cancer cells via activation of the ERK/MMP2/9 signaling axis.
Yang C; Yu H; Chen R; Tao K; Jian L; Peng M; Li X; Liu M; Liu S
Int J Oncol; 2019 Sep; 55(3):684-696. PubMed ID: 31322183
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
8. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Kettner NM; Vijayaraghavan S; Durak MG; Bui T; Kohansal M; Ha MJ; Liu B; Rao X; Wang J; Yi M; Carey JPW; Chen X; Eckols TK; Raghavendra AS; Ibrahim NK; Karuturi MS; Watowich SS; Sahin A; Tweardy DJ; Hunt KK; Tripathy D; Keyomarsi K
Clin Cancer Res; 2019 Jul; 25(13):3996-4013. PubMed ID: 30867218
[TBL] [Abstract][Full Text] [Related]
9. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
[TBL] [Abstract][Full Text] [Related]
10. Baohuoside i suppresses breast cancer metastasis by downregulating the tumor-associated macrophages/C-X-C motif chemokine ligand 1 pathway.
Wang S; Wang N; Huang X; Yang B; Zheng Y; Zhang J; Wang X; Lin Y; Wang Z
Phytomedicine; 2020 Nov; 78():153331. PubMed ID: 32911383
[TBL] [Abstract][Full Text] [Related]
11. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
12. CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy.
Di Sapia R; Zimmer TS; Kebede V; Balosso S; Ravizza T; Sorrentino D; Castillo MAM; Porcu L; Cattani F; Ruocco A; Aronica E; Allegretti M; Brandolini L; Vezzani A
Neurobiol Dis; 2021 Oct; 158():105468. PubMed ID: 34358616
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
14. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
15. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
[TBL] [Abstract][Full Text] [Related]
16. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling.
Wang N; Liu W; Zheng Y; Wang S; Yang B; Li M; Song J; Zhang F; Zhang X; Wang Q; Wang Z
Cell Death Dis; 2018 Aug; 9(9):880. PubMed ID: 30158589
[TBL] [Abstract][Full Text] [Related]
17. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy.
Wang N; Yang B; Muhetaer G; Wang S; Zheng Y; Lu J; Li M; Zhang F; Situ H; Lin Y; Wang Z
Biomed Pharmacother; 2019 Dec; 120():109519. PubMed ID: 31629951
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
19. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation.
Park GY; Pathak HB; Godwin AK; Kwon Y
Cell Oncol (Dordr); 2021 Feb; 44(1):77-92. PubMed ID: 32910411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
